Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AXL1717

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

picropodophyllin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response
Purpose Early phase I study of safety of AXL1717 in patients with recurrent or progressive malignant astrocytomas and evaluation… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
2017
2017
Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer
Abstract Background: The primary objective of this study was to compare the progression-free survival (PFS) at 12 weeks between… Expand
2017
2017
The Prognostic Value of Pre-Treatment Leukocytosis in Patients with Previously Treated, Stage IIIB/IV Non-Small Cell Lung Cancer Treated with the IGF-1R Pathway Modulator AXL1717 or Docetaxel; a…
Background: The aim of the present study was to investigate any prognostic value of pre-treatment anemia, leukocytosis and… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
2015
2015
A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or…
Abstract AXL1717 is an orally bioavailable IGF-1R pathway modulator that has been shown to have anti-tumoral effects. The… Expand
  • table 1
  • table 2
  • table 3
  • table 4
2014
2014
Randomized, controlled, multicenter, multinational phase 2 study of docetaxel (DCT) or AXL1717 treatment in patients with squamous cell carcinoma (SCC) or adenocarcinoma (AC) of non-small cell lung…
8091 Background: AXL1717 (picropodophyllin) is small molecule that inhibits the IGF-1R signaling pathway as well as suppresses… Expand
Review
2012
Review
2012
The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors.
The type 1 insulin-like growth factor receptor (IGF-1R) and its downstream signaling components have become increasingly… Expand
2011
2011
Clinical Phase I study with an Insulin-like Growth Factor-1 Receptor Inhibitor: Experiences in patients with squamous non-small cell lung carcinoma
Abstract Background. Inhibition of the Insulin-like Growth Factor-1 receptor (IGF-1R) has resulted in extensive anti-tumor… Expand
2011
2011
Determination of picropodophyllin and its isomer podophyllotoxin in human serum samples with electrospray ionization of hexylamine adducts by liquid chromatography-tandem mass spectrometry.
A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for determination of the new anticancer agent picropodophyllin… Expand
  • figure 1
  • table 1
  • table 4
  • figure 6
2011
2011
Abstract 1276: A novel targeted oral insulin-like growth factor 1 (IGF-1) receptor inhibitor and its implications for patients with squamous cell lung carcinoma
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Background The incidence of lung cancer has increased… Expand
2010
2010
Clinical phase I/II study with the insulin-like growth factor-1 receptor inhibitor AXL1717: Future implications for patients with squamous non-small cell lung carcinoma?
e13019 Background: Inhibition of the insulin-like growth factor-1 receptor (IGF-1R) has resulted in extensive antitumor effects… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE